409 520

Cited 12 times in

Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study

DC Field Value Language
dc.contributor.author강은석-
dc.contributor.author남정모-
dc.contributor.author이지연-
dc.date.accessioned2019-07-23T06:49:48Z-
dc.date.available2019-07-23T06:49:48Z-
dc.date.issued2019-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/170324-
dc.description.abstractSeveralstudieshave shown that the use ofsulfonylureasinpatientswith type 2 diabetes mellitus (T2DM) is associated with a higherriskofhepatocellular carcinoma(HCC). In thisstudy, we investigated the effects of individualsulfonylureason HCC development using the National Health Insurance Service-National Sample Cohort in South Korea. Among 47,738 subjects aged 40 years or older who had newly diagnosed with diabetes, 241incidentHCC cases and 1205 matched controls were identified. Adjusted odds ratios (ORs) as estimates of the relativeriskof HCC were calculated using logistic regression analysis. Compared topatientsnevertreatedwith asulfonylurea, thosetreatedwith asulfonylureahad a 1.7-fold increasedriskof HCC development. Of the different types ofsulfonylureas, the exclusive use of glimepiride was associated with a significantly elevatedriskof HCC (OR = 1.89, 95% CI = 1.02-3.47) compared to those who were nevertreatedwithsulfonylureas. No significant associations were observed between exclusive gliclazide use andincidentHCC (OR = 2.04, 95% CI = 0.75-5.52). In conclusion, the association between the use ofsulfonylureasandriskof HCC was different according to the type ofsulfonylurea, inpatientswith new-onset T2DM. Further prospectivestudiesare warranted to confirm these results and translate them into clinical practice.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherNature Publishing Group-
dc.relation.isPartOfSCIENTIFIC REPORTS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleIncident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJi-Yeon Lee-
dc.contributor.googleauthorSuk-Yong Jang-
dc.contributor.googleauthorChung Mo Nam-
dc.contributor.googleauthorEun Seok Kang-
dc.identifier.doi10.1038/s41598-019-44447-1-
dc.contributor.localIdA00068-
dc.contributor.localIdA01264-
dc.contributor.localIdA03197-
dc.relation.journalcodeJ02646-
dc.identifier.eissn2045-2322-
dc.identifier.pmid31189966-
dc.contributor.alternativeNameKang, Eun Seok-
dc.contributor.affiliatedAuthor강은석-
dc.contributor.affiliatedAuthor남정모-
dc.contributor.affiliatedAuthor이지연-
dc.citation.volume9-
dc.citation.number1-
dc.citation.startPage8532-
dc.identifier.bibliographicCitationSCIENTIFIC REPORTS, Vol.9(1) : 8532, 2019-
dc.identifier.rimsid61835-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.